Arterial structure and function in Africans with HIV for > 5 years: longitudinal relationship with endothelial activation and cardiovascular risk markers.
HIV
South Africa
arterial injury
large artery stiffness
Journal
HIV medicine
ISSN: 1468-1293
Titre abrégé: HIV Med
Pays: England
ID NLM: 100897392
Informations de publication
Date de publication:
09 2021
09 2021
Historique:
revised:
27
02
2021
received:
12
11
2020
accepted:
22
03
2021
pubmed:
6
5
2021
medline:
15
3
2022
entrez:
5
5
2021
Statut:
ppublish
Résumé
We aimed to determine whether people with human immunodeficiency virus (PWHIV) have increased measures of arterial injury [carotid intima-media thickness (cIMT)] and large artery stiffness [carotid-femoral pulse wave velocity (cfPWV)] when compared with their counterparts without HIV, and whether baseline markers of endothelial activation and cardiovascular risk are associated with cIMT and cfPWV after 5 years. We matched 126 PWHIV from North West Province, South Africa, to 126 without HIV according to age, sex and locality. Cardiovascular risk and endothelial function markers [soluble intracellular adhesion molecule (ICAM-1) and soluble vascular cell adhesion molecule (VCAM-1)] were measured at baseline and cIMT and cfPWV at follow-up. This study included 21.4% men. The use of antiretroviral therapy (ART) increased from 44.1% at baseline to 81.4% at follow-up. At follow-up, cIMT (P = 0.90) and cfPWV (P = 0.35) were similar in the groups. Despite elevated ICAM-1 and VCAM-1 in the PWHIV (all P < 0.001) at baseline, these markers did not associate with cIMT and cfPWV after 5 years. In multivariable-adjusted regression analysis, cIMT associated positively with age (β = 0.31, P = 0.002) and triglyceride: high-density lipoprotein-cholesterol (β = 0.23, P = 0.016) in PWHIV. Mean arterial pressure (MAP) (β = 0.28, P = 0.010) associated positively with cfPWV in the PWHIV. In the people without HIV, sex (β = 0.31, P = 0.004) and glycated haemoglobin (HbA1c) (β = 0.24, P = 0.026) associated with cIMT while age (β = 0.17, P = 0.049), sex (β = 0.29, P = 0.003), MAP (β = 0.31, P = 0.001) and HbA1c (β = 0.21, P = 0.041) associated positively with cfPWV. Measures of arterial structure and function were similar in Africans with HIV and their age, sex and locality matched controls. Traditional cardiovascular risk markers rather than elevated endothelial activation at baseline were independently associated with cIMT and cfPWV over 5 years.
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
650-661Informations de copyright
© 2021 British HIV Association.
Références
Joint United Nations Programme on HIV/AIDS (UNAIDS). GLOBAL HIV STATISTICS. 2019. Available at https://www.unaids.org/sites/default/files/media_asset/UNAIDS_FactSheet_en.pdf (accessed 30 November 2020).
Lozano R, Naghavi M, Foreman K et al. Global and regional mortality from 235 causes of death for 20 age groups in 1990 and 2010: a systematic analysis for the global burden of disease study 2010. Lancet 2012; 380: 2095-2128.
Narayan KVW, Miotti PG, Anand NP et al. HIV and noncommunicable disease comorbidities in the era of antiretroviral therapy: a vital agenda for research in low-and middle-income country settings. J Acquir Immune Defic Syndr 2014; 1: S2-S7.
Maggi P, Lillo A, Perilli F, Maserati R, Chirianni A. Colour-Doppler ultrasonography of carotid vessels in patients treated with antiretroviral therapy: a comparative study. AIDS 2004; 18: 1023-1028.
Lorenz M, Stephan C, Harmjanz A et al. Both long-term HIV infection and highly active antiretroviral therapy are independent risk factors for early carotid atherosclerosis. Atherosclerosis 2008; 196: 720-726.
Seminari E, Pan A, Voltini G et al. Assessment of atherosclerosis using carotid ultrasonography in a cohort of HIV-positive patients treated with protease inhibitors. Atherosclerosis 2002; 162: 433-438.
Lekakis J, Ikonomidis I, Palios J et al. Association of highly active antiretroviral therapy with increased arterial stiffness in patients infected with human immunodeficiency virus. Am J Hypertens 2009; 22: 828-834.
Schillaci G, De Socio GVL, Pucci G et al. Aortic stiffness in untreated adult patients with human immunodeficiency virus infection. Hypertens 2008; 52: 308-313.
Currier JS, Taylor A, Boyd F et al. Coronary heart disease in HIV-infected individuals. J Acquir Immune Defic Syndr 2003; 33: 506-512.
Friis-Møller N, Weber R, Reiss P et al. Cardiovascular disease risk factors in HIV patients-association with antiretroviral therapy. Results from the DAD study. AIDS 2003; 17: 1179-1193.
Klein D, Hurley LB, Quesenberry CP Jr, Sidney S. Do protease inhibitors increase the risk for coronary heart disease in patients with HIV-1 infection? J Acquir Immune Defic Syndr 2002; 30: 471-477.
Triant VA. Epidemiology of coronary heart disease in HIV patients. Rev Cardiovasc Med 2014; 15: S1-S08.
Vos AG, Idris NS, Barth RE, Klipstein-Grobusch K, Grobbee DE. Pro-inflammatory markers in relation to cardiovascular disease in HIV infection. A systematic review. PLoS One 2016; 11: 1-11.
Souza SJ, Luzia LA, Santos SS, Rondó PHC. Lipid profile of HIV-infected patients in relation to antiretroviral therapy: a review. Rev Assoc Med Bras 2013; 59: 186-198.
Mbunkah HA, Meriki HD, Kukwah AT, Nfor O, Nkuo-Akenji T. Prevalence of metabolic syndrome in human immunodeficiency virus-infected patients from the South-West region of Cameroon, using the adult treatment panel III criteria. Diabetol Met Syndr 2014; 6: 1-14.
Marfell-Jones M, Olds T, Stewart A, Carter L. International standards for anthropometric assessment. Potchefstroom, South Africa: International Society for the Advancement of Kinanthropometry (ISAK). 2006. Available at https://www.worldcat.org/title/international-standards-for-anthropometric-assessment/oclc/156766813 (accessed 24 February 2021).
Triant VA, Lee H, Hadigan C, Grinspoon SK. Increased acute myocardial infarction rates and cardiovascular risk factors among patients with human immunodeficiency virus disease. J Clin Endocrinol Metab 2007; 92: 2506-2512.
McCutchan FE. Global epidemiology of HIV. J Med Virol 2006; 78: S7-S12.
Graham SM, Rajwans N, Jaoko W et al. Endothelial activation biomarkers increase after HIV-1 acquisition: plasma vascular cell adhesion molecule-1 predicts disease progression. AIDS 2013; 27: 1803-1813.
Bongard V, Elias A, Bal dit Sollier C et al. Soluble intercellular adhesion molecule-1 is associated with carotid and femoral atherosclerosis but not with intima-media thickness in a population-based sample. Atherosclerosis 2002; 164: 297-304.
Amar J, Fauvel J, Drouet L et al. Interleukin 6 is associated with subclinical atherosclerosis: a link with soluble intercellular adhesion molecule 1. J Hypertens 2006; 24: 1083-1088.
Fourie C, Schutte AE, Smith W, Kruger A, van Rooyen JM. Endothelial activation and cardiometabolic profiles of treated and never-treated HIV infected Africans. Atherosclerosis 2015; 240: 154-160.
Rayner B, Jones E, Veriava Y, Seedat YK. South African hypertension society commentary on the American College of Cardiology/American Heart Association hypertension guidelines. Cardiovasc J Afr 2019; 30: 184-187.
Liang ZP, Lauterbur PC. Principles of magnetic resonance imaging: a signal processing perspective. New York, NY, “The” Institute of Electrical and Electronics Engineers Press, 2000.
Wendelhag I, Liang Q, Gustavsson T, Wikstrand J. A new automated computerized analyzing system simplifies readings and reduces the variability in ultrasound measurement of intima-media thickness. Stroke 1997; 28: 2195-2200.
Johnson R, McNutt P, MacMahon S, Robson R. Use of the Friedewald formula to estimate LDL-cholesterol in patients with chronic renal failure on dialysis. Clin Chem 1997; 43: 2183-2184.
Phalane E, Fourie CMT, Mels CMC, Schutte AE. A 10-year follow-up study of demographic and cardiometabolic factors in HIV-infected South Africans: cardiovascular topics. Cardiovasc J Afr 2019; 30: 352-360.
Beneto A, Weaber B, Izzo J et al. Influence of age, risk factors, and cardiovascular and renal disease on arterial stiffness: clinical applications. Am J Hyperten 2002; 15: 1101-1108.
Statics South Africa. Mid-year population estimates. 2020. Available at http://www.statssa.gov.za/publications/P0302/P03022020.pdf (accessed 18 February 2021).
Mosepele M, Hemphill LC, Moloi W et al. Pre-clinical carotid atherosclerosis and sCD163 among virally suppressed HIV patients in Botswana compared with uninfected controls. PLoS One 2017; 12: e0179994-e0179998.
Baker JV, Henry WK, Patel P et al. Progression of carotid intima-media thickness in a contemporary human immunodeficiency virus cohort. Clin Infect Dis 2011; 53: 826-835.
Jericó C, Knobel H, Calvo N et al. Subclinical carotid atherosclerosis in HIV-infected patients: role of combination antiretroviral therapy. Stroke 2006; 37: 812-817.
Monteiro P, Miranda-Filho DB, Bandeira F et al. Is arterial stiffness in HIV-infected individuals associated with HIV-related factors? Braz J Med Biol Res 2012; 45: 818-826.
Ferraioli G, Tinelli C, Maggi P et al. Arterial stiffness evaluation in HIV-positive patients: a multicenter matched control study. Am J Roentgenol 2011; 197: 1258-1262.
Lewis W. Atherosclerosis in AIDS: potential pathogenetic roles of antiretroviral therapy and HIV. J Mol Cell 2000; 32: 2115-2129.
Ho JE, Deeks SG, Hecht FM et al. Initiation of antiretroviral therapy at higher nadir CD4+ T-cell counts is associated with reduced arterial stiffness in HIV-infected individuals. AIDS 2010; 412: 1897-1905.
van Vonderen MG, Smulders YM, Stehouwer CDA et al. Carotid intima-media thickness and arterial stiffness in HIV-infected patients: the role of HIV, antiretroviral therapy, and lipodystrophy. J Acquir Immune Defic Syndr 2009; 50: 153-161.
South Africa: Department of Health (SADoH). Clinical guidelines for the management of HIV & AIDS in adults and adolescents 2010. 2010. Available at https://sahivsoc.org/Files/Clinical_Guidelines_for_the_Management_of_HIV_AIDS_in_Adults_Adolescents_2010.pdf (accessed 30 November 2020).
Ross AC, Rizk N, O'Riordan MA et al. Relationship between inflammatory markers, endothelial activation markers, and carotid intima-media thickness in HIV-infected patients receiving antiretroviral therapy. Clin Infect Dis 2009; 49: 1119-1127.
Gross MD, Bielinski SJ, Suarez-Lopez JR et al. Circulating soluble intercellular adhesion molecule 1 and subclinical atherosclerosis: the coronary artery risk development in young adults study. Clin Chem 2012; 58: 411-420.
Safar ME, Levy BI, Struijker-Boudier H. Current perspectives on arterial stiffness and pulse pressure in hypertension and cardiovascular diseases. Circulation 2003; 107: 2864-2869.
van Zoest RA, Wit FW, Kooij KW et al. Higher prevalence of hypertension in HIV-1-infected patients on combination antiretroviral therapy is associated with changes in body composition and prior stavudine exposure. Clin Infect Dis 2016; 63: 205-213.
Peck RN, Shedafa R, Kalluvya S et al. Hypertension, kidney disease, HIV and antiretroviral therapy among Tanzanian adults: a cross-sectional study. BMC Med 2014; 12: 1-11.
Thiébaut R, El-Sadr WM, Friss-Moller N et al. Predictors of hypertension and changes of blood pressure in HIV-infected patients. Antivir Ther 2005; 10: 811-823.
Feigl AB, Bloom DE, Danaei G et al. The effect of HIV and the modifying effect of anti-retroviral therapy (ART) on body mass index (BMI) and blood pressure levels in rural South Africa. PLoS One 2016; 11: 1-45.
Gazzaruso C, Brubo R, Garzaniti A et al. Hypertension among HIV patients: prevalence and relationships to insulin resistance and metabolic syndrome. J hypertens 2003; 21: 1377-1382.
Rider OJ, Asaad M, Ntusi N et al. HIV is an independent predictor of aortic stiffness. J Cardiovasc Magn Reson 2014; 16: 1-9.
Wilkinson I, Cockcroft JR. Cholesterol, lipids and arterial stiffness, in Atherosclerosis, large arteries and cardiovascular risk. 2007. Adv Cardiol 2007; 44: 261-277.
Effros RB, Fletcher CV, Gebo K et al. Workshop on HIV infection and aging: what is known and future research directions. Clin Infect Dis 2008; 47: 542-553.
Guaraldi G, Zona S, Alexopoulos N et al. Coronary aging in HIV-infected patients. Clin Infect Dis 2009; 49: 1756-1762.
Kim PS, Woods C, Georgoff P et al. A1C underestimates glycemia in HIV infection. Diabetes Care 2009; 32: 1591-1593.